SELLAS Life Sciences Group Q1 2024 Earnings Report

SELLAS Life Sciences Group EPS Results

• Actual EPS: -$0.21
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SELLAS Life Sciences Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SELLAS Life Sciences Group Announcement Details

• Quarter: Q1 2024
• Date: 5/14/2024
• Time: N/A
• Conference Call Date: Tuesday, May 14, 2024
• Conference Call Time: 7:00AM ET

SELLAS Life Sciences Group (NASDAQ:SLS) is a clinical‐stage biotechnology company focused on the discovery, development and commercialization of novel immunotherapies for the treatment of cancer. Utilizing its proprietary tumor antigen platform, the company’s core strategy centers on engineering T cells and antibody‐based constructs to recognize aberrant glycopeptide markers on solid tumors. SELLAS has advanced its lead candidate into early‐phase clinical trials and continues to build a diversified pipeline aimed at addressing high‐unmet‐need oncology indications.

The company’s flagship program, a CAR T‐cell therapy targeting the Tn‐MUC1 glycopeptide antigen, has entered Phase 1 studies in patients with platinum‐resistant ovarian cancer and peritoneal mesothelioma. In parallel, SELLAS is advancing a bispecific T cell engager directed against the same Tn‐MUC1 target to recruit and activate endogenous T cells within the tumor microenvironment. Preclinical work has demonstrated promising tumor localization and cell‐killing activity, supporting ongoing IND‐enabling efforts and potential combination strategies with immune checkpoint inhibitors.

Founded in the mid-2000s and headquartered in New York with additional laboratory facilities in Pennsylvania, SELLAS has assembled a leadership team with extensive experience in cell and gene therapy, oncology drug development and regulatory affairs. Under the guidance of President and Chief Executive Officer Robert B. Hoffman, the organization has forged collaborations with leading academic centers and contract development partners to drive clinical trial execution and manufacturing scale-up. Its global trial footprint spans the United States and select European sites, reflecting a commitment to enrolling diverse patient populations.

Beyond its proprietary pipeline, SELLAS maintains an active discovery research effort aimed at identifying new glycopeptide targets and optimizing T cell engineering platforms. The company leverages both in‐house capabilities and external partnerships to accelerate translational studies, with a longer‐term goal of establishing multiple immuno‐oncology products for commercial launch. As clinical data mature, SELLAS intends to expand its development programs into additional solid tumor indications and explore strategic collaborations to maximize patient access.